<DOC>
	<DOCNO>NCT00088166</DOCNO>
	<brief_summary>The purpose study compare safety efficacy XERECEPT® dexamethasone ( Decadron ) common treatment symptom brain swelling ( edema ) . This study specifically aim patient require chronic high dos dexamethasone manage symptom .</brief_summary>
	<brief_title>XERECEPT® ( hCRF ) Patients Requiring Dexamethasone Treat Edema Associated With Brain Tumors</brief_title>
	<detailed_description>XERECEPT® potential treatment cancer , may reduce edema associate tumor result , decrease neurological symptom .</detailed_description>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Brain Edema</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Corticotropin-Releasing Hormone</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Histologically confirm diagnosis primary malignant brain tumor , metastatic , documentation histology ( available ) primary source cancer . Patient must 1 qualify steroidassociated side effect ( ) Baseline . Patient require administration dexamethasone control symptoms peritumoral edema least 30 day . Stable dexamethasone dose 424 mg/day least 14 day prior Baseline . Need administration dexamethasone treat peritumoral brain edema ( reference ) document MRI comparable diagnostic technology within 21 day Baseline . Karnofsky score &gt; 50 Screening Baseline . Capable selfadministration subcutaneous injection twice daily 12 week , availability assistance caregiver . Ability provide write informed consent , unable provide , legal guardian representative provide write informed consent . For woman childbearing potential : negative serum pregnancy test Screening . Must 18 year age old Ongoing anticipate need surgery , radiosurgery radiation therapy introduction new chemotherapeutic regime within first 5 week study enrollment . Treatment prestudy chemotherapy may continue . Concurrent enrollment investigational drug device study , plan enroll study first 5 week treatment . Systemic steroid use indication peritumoral brain edema . Use intend use dexamethasone antiemetic Screening Study Noncompliance dexamethasone anticonvulsant therapy . Clinical sign symptom cerebral herniation . Serious concomitant cardiovascular , pulmonary , renal , gastrointestinal endocrine metabolic disease could put patient unusual risk study participation . Confounding previous concurrent neurological disorder would interfere adequate clinical evaluation . Clinically significant head injury chronic seizure disorder , condition result functional impairment likely interfere evaluation . ( Maintenance anticonvulsant therapy allow . ) Central nervous system infection . Pregnancy , breastfeed and/or refusal practice birth control study , woman childbearing potential . Any condition consider contraindication patient receive niacin , e.g . liver disease ( LFTs &gt; 3 time upper limit norm ) , active peptic ulcer , arterial hemorrhage , asthma know hypersensitivity niacin .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>peritumoral brain edema</keyword>
	<keyword>edema</keyword>
	<keyword>malignant brain tumor</keyword>
	<keyword>astrocytoma</keyword>
	<keyword>brain tumor</keyword>
	<keyword>dexamethasone</keyword>
	<keyword>Decadron</keyword>
</DOC>